- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03249493
Monitoring Of Viral Load In Decentralised Area in Vietnam (MOVIDA-2)
Monitoring Of Viral Load In Decentralised Area in Vietnam : Improving Access to Viral Load Monitoring in HIV-infected Patients on ART
As of today, HIV-infected patients followed in decentralized area have little or even no access to viral load monitoring because laboratories able to perform this biological measurement are only in large cities, and because plasma transfer to these laboratories is complex and very costly.
Blood sampling using dried blood spots (DBS) could overcome these difficulties. The goal of this operational research is to document the feasibility of DBS use in decentralised area to monitor viral load, to evaluate the virological response on ART, and to compare the virological response between injecting drug users (IDU) and the other patients, as IDU represent a large proportion of HIV-infected patients who may have a lower access/adherence to care.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The MOVIDA project is a longitudinal observational study enrolling patients who initiate ART in decentralized areas requiring individual data and blood samples collected in routine HIV care.
This project aims at evaluating and providing operability data of the use of Dried Blood Spots (DBS) as sampling tool to measure and monitor the HIV viral load in real life in rural decentralized areas in Vietnam.
This operational project would contribute to:
- the provision of viral load measurements in patients from rural decentralized areas,
- the improvement of the proportion of patients in virological success on ART, and hence to reduce the proportion of patients with acquired HIV drug resistance,
- the improvement of general HIV care and to establish an observatory of HIV drug resistance,
- strengthen national capacities through capitalization and exchange of good practices of blood sampling using DBS system to expand to other indications than HIV VL measurement.
To achieve this goal, clinical and laboratory staff will be trained to the management of the MOVIDA project (enrollment of patients; sample collection, management and analysis; data collection) before the operational observational study. Patients on the antiretroviral (ART) initiation visit will be informed about the study and invited to participate, before collection of blood to prepare DBS and collection of clinical data already routinely collected in the patient medical records. The blood collection (5ml) will be repeated at 6, 12 and 24 months during follow-up visits already planned according to the current national guidelines for the ART delivery.
The samples collected (5ml of blood) will be analyzed in a local central laboratory using the m2000rt Abbott techniques. Analysis results (VL and when necessary HIV Drug Resistance genotyping) will be available to the medical doctor in order to adapt the patient treatment appropriately. A set of randomly selected DBS will be shipped to France for centralized quality control analyses.
A socio-anthropological qualitative study will also be implemented targeting patients, health-care staff and peer health workers to apprehend their understanding of VL, and to better define determinants of adherence and attendance to clinical visits. This will help local health authorities adapt the messages and the initiatives to improve adherence to ART and attendance to care follow-up.
The study duration is 36 months with a 6 months period of enrollment and will be conducted in 6 provinces where 1000 patients are to be enrolled.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Yen Bai, Vietnam
- Yen Bai medical center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- confirmed HIV-1 infection,
- age at enrolment ≥18 years,
- ART naïve (women exposed through PMTCT are eligible),
- consent to participate.
Exclusion Criteria:
- negative for HIV,
- age at enrolment <18 years,
- ART experienced (excepted PMTCT),
- not consenting to participate.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HIV Injection drug users
Blood sample on DBS.
Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
|
We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards. HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results > 1000 cp/mL |
HIV Non injection drug users
Blood sample on DBS.
Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
|
We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards. HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results > 1000 cp/mL |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Virological success at 24 months of ART
Time Frame: 24 months (+/- 1 month) after ART initiation
|
Patients with a VL <1000 copies/mL at 24 months of ART
|
24 months (+/- 1 month) after ART initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Outcomes related to DBS transfer
Time Frame: through study completion, an average of 2 years
|
|
through study completion, an average of 2 years
|
Outcomes related to quality of DBS samples
Time Frame: through study completion, an average of 2 years
|
- Aspect of DBS at reception at central laboratory (qualitative evaluation)
|
through study completion, an average of 2 years
|
Outcomes related to delay concerning the return of viral load result
Time Frame: through study completion, an average of 2 years
|
|
through study completion, an average of 2 years
|
Outcomes related to ability of DBS to provide viral load result
Time Frame: through study completion, an average of 2 years
|
- Proportion of DBS not allowing viral load quantification (number of DBS not allowing VL quantification/total number of DBS samples)
|
through study completion, an average of 2 years
|
Outcomes related to ability of DBS to provide HIV drug resistance result
Time Frame: through study completion, an average of 2 years
|
- Proportion of DBS not allowing HIV drug resistance (number of DBS not allowing HIV drug resistance /total number of DBS samples with VL confirmed>1000cp/mL)
|
through study completion, an average of 2 years
|
Impact of viral load result on second-line ART initiation
Time Frame: through study completion, an average of 2 years
|
- Number of patients who initiate second-line ART during the study
|
through study completion, an average of 2 years
|
Impact of viral load result on second-line ART initiation in term of delay
Time Frame: through study completion, an average of 2 years
|
- Delay (days) between reception of the viral load results at the care site and second-line ART initiation
|
through study completion, an average of 2 years
|
virological success at 6 and at 12 months of ART
Time Frame: At 6 and 12 months of ART
|
Patients with a VL <1000 copies/mL at 6 and at 12 months of ART
|
At 6 and 12 months of ART
|
Virological failure at 6, 12 and 24 months of ART
Time Frame: At 6, 12 and 24 months of ART
|
- Proportion of patients with 2 consecutive viral load >= 1000 copies/mL (the second viral load being measured within 2 to 3 months from the first one after strengthening of adherence)
|
At 6, 12 and 24 months of ART
|
HIV drug resistance in case of virological failure at 6, 12 and 24 months of ART
Time Frame: At 6, 12 and 24 months of ART
|
- Proportion of patients in virological failure and for whom the virus is harbouring HIV drug resistances
|
At 6, 12 and 24 months of ART
|
Description of HIV drug resistance in case of virological failure at 6, 12 and 24 months of ART
Time Frame: At 6, 12 and 24 months of ART
|
- Profiles of HIV durg resistance in patients in virological failure
|
At 6, 12 and 24 months of ART
|
Baseline HIV drug resistance in case of virological failure
Time Frame: ART initiation
|
- Proportion of patients identified in virological failure during the follow-up on ART, and for whom the virus presented HIV drug resistance at ART initiation
|
ART initiation
|
Baseline HIV drug resistance
Time Frame: ART initiation
|
- proportion of patients for whom the virus presented HIV drug resistance at ART initiation, in a random selection of patients enrolled
|
ART initiation
|
Mortality
Time Frame: through study completion, an average of 2 years
|
Patients who died while on ART during the follow-up
|
through study completion, an average of 2 years
|
Attrition
Time Frame: through study completion, an average of 2 years
|
patients who are lost to follow-up (not seen for >3 months) after they initiated ART
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fabien Taieb, MD, Institut Pasteur
- Principal Investigator: Yoann MADEC, PhD, Institut Pasteur
Publications and helpful links
General Publications
- Taieb F, Tran Hong T, Ho HT, Nguyen Thanh B, Pham Phuong T, Viet Ta D, Le Thi Hong N, Ba Pham H, Nguyen LTH, Nguyen HT, Nguyen TT, Tuaillon E, Delaporte E, Le Thi H, Tran Thi Bich H, Nguyen TA, Madec Y. First field evaluation of the optimized CE marked Abbott protocol for HIV RNA testing on dried blood spot in a routine clinical setting in Vietnam. PLoS One. 2018 Feb 9;13(2):e0191920. doi: 10.1371/journal.pone.0191920. eCollection 2018.
- Taieb F, Tram TH, Ho HT, Pham VA, Nguyen L, Pham BH, Tong LA, Tuaillon E, Delaporte E, Nguyen AT, Bui DD, Do N, Madec Y. Evaluation of Two Techniques for Viral Load Monitoring Using Dried Blood Spot in Routine Practice in Vietnam (French National Agency for AIDS and Hepatitis Research 12338). Open Forum Infect Dis. 2016 Jul 7;3(3):ofw142. doi: 10.1093/ofid/ofw142. eCollection 2016 Sep.
- Nguyen TA, Tran TH, Nguyen BT, Pham TTP, Hong Le NT, Ta DV, Phan HTT, Nguyen LH, Ait-Ahmed M, Ho HT, Taieb F, Madec Y; MOVIDA 2 study group. Feasibility of dried blood spots for HIV viral load monitoring in decentralized area in North Vietnam in a test-and-treat era, the MOVIDA project. PLoS One. 2020 Apr 9;15(4):e0230968. doi: 10.1371/journal.pone.0230968. eCollection 2020.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 2016-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on Blood sample on DBS
-
University of British ColumbiaNot yet recruiting
-
Functional Neuromodulation LtdActive, not recruitingAlzheimer DiseaseUnited States, Canada, Germany
-
Centre Hospitalier Universitaire DijonCompleted
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
-
Xuanwu Hospital, BeijingBeijing Pins Medical Co., LtdUnknown
-
Ruijin HospitalActive, not recruitingMajor Depressive Disorder | Deep Brain StimulationChina
-
University of DundeeCompletedOvarian Cancer | Lung Cancer, Non-small Cell | Melanoma Stage IV | Melanoma Stage III | Renal Cancer Stage III | Renal Cancer Stage IVUnited Kingdom
-
University Hospital, GrenobleCompleted
-
University Hospital, GrenobleUnknownPsychiatric Disorder | Motor Disorders
-
Assistance Publique - Hôpitaux de ParisCompletedLiver Transplant; Complications